Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design, synthesis and biological evaluation of pyrazolo[3,4-<i>b</i>]pyridine derivatives as dual CDK2/PIM1 inhibitors with potent anti-cancer activity and selectivity.

Journal of biomolecular structure & dynamics·2025
Same author

Theoretical study of the antioxidant mechanism and structure-activity relationships of 1,3,4-oxadiazol-2-ylthieno[2,3-d]pyrimidin-4-amine derivatives: a computational approach.

Frontiers in chemistry·2024
Same author

New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with <i>in silico</i> docking, ADMET, toxicity, and DFT studies.

RSC advances·2022
Same author

Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-<i>a</i>:3',4'-<i>c</i>]quinoxaline derivatives as anticancer agents and apoptosis inducers.

Journal of enzyme inhibition and medicinal chemistry·2021
Same author

New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.

Bioorganic chemistry·2021

Related Experiment Video

Updated: May 31, 2025

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Nateglinide: A comprehensive profile.

Manal M Alanazi1

  • 1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|January 24, 2025
PubMed
Summary

Nateglinide, an oral hypoglycemic agent, stimulates insulin secretion by targeting pancreatic beta cells. This review details its synthesis, properties, structural determination, analytical methods, and pharmacological profile for type 2 diabetes management.

Keywords:
Antihyperglycemic agentChromatographicImpuritiesInsulin secretagogueNateglinidePharmacologyPhysical and chemical characteristicPreparation methodSpectroscopyUses and applications

More Related Videos

Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.3K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

10.9K

Related Experiment Videos

Last Updated: May 31, 2025

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.3K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

10.9K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Analytical Chemistry

Background:

  • Nateglinide is a meglitinide class insulin secretagogue used for type 2 diabetes mellitus.
  • It is a D-phenylalanine derivative that modulates ATP-sensitive potassium channels in pancreatic beta cells.
  • Stimulates insulin secretion to manage blood glucose levels.

Purpose of the Study:

  • To provide a comprehensive overview of Nateglinide.
  • Discuss synthesis, physicochemical properties, and structural elucidation techniques.
  • Review analytical methodologies and pharmacological aspects.

Main Methods:

  • Structural determination methods include elemental analysis, IR, UV, NMR (¹H and ¹³C), MS, and XRD.
  • Analytical methods reviewed encompass X-ray powder diffraction, DSC, spectrophotometry, chromatography, capillary electrophoresis, and immunoassays.
  • Pharmacological review includes pharmacokinetics, pharmacodynamics, mechanism of action, and drug interactions.

Main Results:

  • Detailed discussion on the synthesis and characterization of Nateglinide.
  • Comprehensive review of diverse analytical techniques for Nateglinide quantification and identification.
  • Summary of Nateglinide's pharmacological profile, including interactions.

Conclusions:

  • Nateglinide is a significant oral hypoglycemic agent with a well-defined mechanism of action.
  • A variety of analytical methods are available for its characterization and quality control.
  • Understanding its pharmacology is crucial for effective diabetes management.